Advances in Therapy

, Volume 28, Issue 7, pp 566–574 | Cite as

Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis

  • Shachar Tauber
  • Gale Cupp
  • Richard Garber
  • John Bartell
  • Firoz Vohra
  • David Stroman
Open Access
Original Research



An alternative formulation of 0.5% moxifloxacin ophthalmic solution (Moxeza®, MOXI-AF, Alcon Laboratories, Inc., Fort Worth, TX, USA) containing xanthan gum to prolong retention on the eye has been developed. MOXI-AF was designed to optimize the treatment regimen for bacterial conjunctivitis for the convenience of the patient with twice-daily dosing.


A safety and efficacy clinical study was conducted as a multicenter, vehiclecontrolled, randomized, double-masked, parallel group study in clinically diagnosed bacterial conjunctivitis patients aged >28 days. MOXI-AF or its vehicle was dosed one drop twice-daily for 3 days. Microbiological specimens were obtained from affected eyes on day 1, prior to the initial dose, and on day 4 after 3 days of dosing, and processed using routine clinical microbiology laboratory methods. All recovered bacteria were identified to the species level.


This paper reports on the microbiological success rate, a secondary efficacy variable in the trial. All patients (1180) were randomized to treatment. Patient age ranged from 30 days to 92 years. The microbiological success rate for patients treated topically with MOXI-AF twice-daily for 3 days was 74.5%, compared with 56.0% of patients treated with its vehicle control (P<0.0001). MOXI-AF was also statistically more effective than vehicle in eradicating the three principle conjunctivitis pathogens, Haemophilus influenzae (98.5% vs. 59.6%, respectively), Streptococcus pneumoniae (86.4% vs. 50.0%, respectively), and Staphylococcus aureus (94.1% vs. 80.0%, respectively) (P<0.001).


The xanthan gum-based 0.5% moxifloxacin ophthalmic formulation, MOXI-AF, provides effective eradication of the three principle causative pathogens of bacterial conjunctivitis across all age groups when dosed twice-daily for 3 days.


bacterial conjunctivitis fluoroquinolone microbial efficacy moxifloxacin ophthalmic solution 


  1. 1.
    Drancourt M, Herbert L. Conjunctivitis, keratitis and infections of periorbital structures. In: Cohen J, Powderly WG, Opal SM, eds. Cohen & Powderly: Infectious Diseases. 3 ed. Mosby, an Imprint of Elsevier, Inc.; 2010.Google Scholar
  2. 2.
    Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J. 2005;24:823–828.PubMedCrossRefGoogle Scholar
  3. 3.
    Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of state departments of health. J Pediatr Ophthalmol Strabismus. 2007;44:101–5.PubMedGoogle Scholar
  4. 4.
    Lichtenstein SJ, Dorfman M, Kennedy R, Stroman D. Controlling contagious bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2006;43:19–26.PubMedGoogle Scholar
  5. 5.
    CDC. Outbreak of bacterial conjunctivitis at a college — New Hampshire, January-March, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:205–207.Google Scholar
  6. 6.
    CDC. Pneumococcal conjunctivitis at an elementary school — Maine, September 20–December 6, 2002. MMWR Morb Mortal Wkly Rep. 2002;52:64–66.Google Scholar
  7. 7.
    Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003;348:1112–1121.PubMedCrossRefGoogle Scholar
  8. 8.
    D’Arienzo PA, Wagner RS, Jamison T, Bell B, Dajcs JJ, Stroman DW. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens. Adv Ther 2010;27:39–47.PubMedCrossRefGoogle Scholar
  9. 9.
    Wagner RS, Granet DB, Lichtenstein SJ, et al. Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin. Clin Ophthalmol. 2010;4:41–45.PubMedGoogle Scholar
  10. 10.
    Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2006;CD001211.Google Scholar
  11. 11.
    Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005;50(Suppl. 1):S16–S31.PubMedCrossRefGoogle Scholar
  12. 12.
    Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86:5–17.PubMedGoogle Scholar

Copyright information

© Springer Healthcare 2011

Authors and Affiliations

  • Shachar Tauber
    • 1
  • Gale Cupp
    • 2
  • Richard Garber
    • 2
  • John Bartell
    • 2
  • Firoz Vohra
    • 2
  • David Stroman
    • 2
  1. 1.St. John’s Clinic — Eye SpecialistsSpringfieldUSA
  2. 2.Alcon Research, Ltd.Fort WorthUSA

Personalised recommendations